MY166210A - Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition - Google Patents

Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition

Info

Publication number
MY166210A
MY166210A MYPI2016001268A MYPI2016001268A MY166210A MY 166210 A MY166210 A MY 166210A MY PI2016001268 A MYPI2016001268 A MY PI2016001268A MY PI2016001268 A MYPI2016001268 A MY PI2016001268A MY 166210 A MY166210 A MY 166210A
Authority
MY
Malaysia
Prior art keywords
castor oil
pharmaceutical composition
acid compound
polyoxyl
polyoxyethylene castor
Prior art date
Application number
MYPI2016001268A
Other languages
English (en)
Inventor
Yoko Endo
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of MY166210A publication Critical patent/MY166210A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MYPI2016001268A 2014-01-10 2015-01-08 Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition MY166210A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014002809 2014-01-10

Publications (1)

Publication Number Publication Date
MY166210A true MY166210A (en) 2018-06-22

Family

ID=53523959

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2016001268A MY166210A (en) 2014-01-10 2015-01-08 Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition

Country Status (19)

Country Link
US (3) US20160317512A1 (enExample)
EP (2) EP3888654B1 (enExample)
JP (5) JP6012775B2 (enExample)
KR (6) KR101858373B1 (enExample)
CN (2) CN105828817B (enExample)
AU (1) AU2015205268B2 (enExample)
BR (1) BR112016015911B1 (enExample)
CA (1) CA2934612C (enExample)
EA (1) EA031723B1 (enExample)
ES (2) ES2953346T3 (enExample)
GE (1) GEP20186916B (enExample)
IL (1) IL246654B (enExample)
MX (1) MX2016009058A (enExample)
MY (1) MY166210A (enExample)
PH (1) PH12016501327A1 (enExample)
SG (1) SG11201605532YA (enExample)
TW (1) TWI612960B (enExample)
UA (1) UA121744C2 (enExample)
WO (1) WO2015105134A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3093019B1 (en) * 2014-01-10 2021-05-26 Santen Pharmaceutical Co., Ltd Pharmaceutical composition containing pyridylamino acetic acid compound
KR101858373B1 (ko) * 2014-01-10 2018-05-15 산텐 세이야꾸 가부시키가이샤 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물
TR201902019T4 (tr) 2014-01-10 2019-03-21 Santen Pharmaceutical Co Ltd Piridilamino asetik asit bileşiği içeren farmasötik preparasyon.
US20180200239A1 (en) 2015-07-09 2018-07-19 Santen Pharmaceutical Co., Ltd. Prophylactic and/or therapeutic agent containing pyridylaminoacetic acid compound
WO2018230713A1 (ja) 2017-06-16 2018-12-20 学校法人同志社 カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用
WO2018230711A1 (ja) 2017-06-16 2018-12-20 学校法人同志社 mTORインヒビターを含む、眼の症状、障害または疾患を治療または予防するための医薬およびその応用
JP7250685B2 (ja) * 2017-09-29 2023-04-03 参天製薬株式会社 ピリジルアミノ酢酸化合物を含有する医薬
JPWO2019124487A1 (ja) 2017-12-21 2020-12-10 参天製薬株式会社 オミデネパグの組合せ
CN111526876A (zh) 2017-12-28 2020-08-11 参天制药株式会社 含有吡啶基氨基乙酸化合物的药物制剂
JP7217364B2 (ja) * 2019-11-29 2023-02-02 千寿製薬株式会社 医薬組成物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960799A (en) * 1988-09-13 1990-10-02 Ciba-Geigy Corporation Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
JP3297969B2 (ja) * 1994-12-26 2002-07-02 ライオン株式会社 点眼剤
DE69922916T2 (de) * 1998-07-14 2005-06-09 Alcon Manufacturing Ltd., Fort Worth Polypropylenbasierte behälter für prostaglandin-enthaltende produkte
US6235781B1 (en) * 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
US20020009507A1 (en) * 2000-01-19 2002-01-24 Alcon Universal Ltd. Use of polyethoxylated castor oil for the treatment of dry eye
JP2002356420A (ja) * 2001-03-27 2002-12-13 Santen Pharmaceut Co Ltd 安定な水性液剤
SI2264009T1 (sl) * 2008-03-12 2019-05-31 Ube Industries, Ltd. Spojina piridilaminoocetne kisline
PT2415763E (pt) 2009-03-30 2016-03-30 Ube Industries Composição farmacêutica para tratamento ou prevenção do glaucoma
JP2011057633A (ja) * 2009-09-11 2011-03-24 Ube Industries Ltd ピリジルアミノ酢酸化合物を含有する医薬
US20120058983A1 (en) * 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
US20140018350A1 (en) * 2012-07-13 2014-01-16 Asahi Glass Co., Ltd. Combination of sulfonamide compound and tafluprost
JP6193655B2 (ja) * 2012-07-13 2017-09-06 参天製薬株式会社 スルホンアミド化合物の組み合わせ
US9339496B2 (en) * 2012-07-13 2016-05-17 Santen Pharmaceutical Co., Ltd. Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist
JP2014019650A (ja) * 2012-07-13 2014-02-03 Santen Pharmaceut Co Ltd スルホンアミド化合物とタフルプロストの組み合わせ
KR101858373B1 (ko) * 2014-01-10 2018-05-15 산텐 세이야꾸 가부시키가이샤 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물
TR201902019T4 (tr) * 2014-01-10 2019-03-21 Santen Pharmaceutical Co Ltd Piridilamino asetik asit bileşiği içeren farmasötik preparasyon.
EP3093019B1 (en) * 2014-01-10 2021-05-26 Santen Pharmaceutical Co., Ltd Pharmaceutical composition containing pyridylamino acetic acid compound

Also Published As

Publication number Publication date
BR112016015911B1 (pt) 2022-04-05
KR20200053651A (ko) 2020-05-18
JP7546027B2 (ja) 2024-09-05
US20160317512A1 (en) 2016-11-03
BR112016015911A2 (enExample) 2017-08-08
EA201691139A1 (ru) 2017-02-28
NZ721530A (en) 2021-03-26
JP6449205B2 (ja) 2019-01-09
CN105828817B (zh) 2019-07-05
JP2015147762A (ja) 2015-08-20
JP2021011508A (ja) 2021-02-04
KR20240096869A (ko) 2024-06-26
EP3888654A1 (en) 2021-10-06
TWI612960B (zh) 2018-02-01
CA2934612C (en) 2021-09-07
KR20160100977A (ko) 2016-08-24
PH12016501327B1 (en) 2017-02-06
EP3888654B1 (en) 2023-06-14
EP3093021A1 (en) 2016-11-16
ES2874547T3 (es) 2021-11-05
EA031723B1 (ru) 2019-02-28
TW201611833A (en) 2016-04-01
KR102458180B1 (ko) 2022-10-21
IL246654B (en) 2020-05-31
CN110251516B (zh) 2022-05-03
US20200113880A1 (en) 2020-04-16
KR102675685B1 (ko) 2024-06-14
JP6012775B2 (ja) 2016-10-25
JP6793172B2 (ja) 2020-12-02
KR102230683B1 (ko) 2021-03-19
KR20220146691A (ko) 2022-11-01
SG11201605532YA (en) 2016-08-30
AU2015205268B2 (en) 2019-03-14
CN110251516A (zh) 2019-09-20
WO2015105134A1 (ja) 2015-07-16
ES2953346T3 (es) 2023-11-10
JP2017031177A (ja) 2017-02-09
CA2934612A1 (en) 2015-07-16
UA121744C2 (uk) 2020-07-27
MX2016009058A (es) 2016-09-09
HK1224191A1 (zh) 2017-08-18
JP2019034973A (ja) 2019-03-07
EP3093021A4 (en) 2017-07-26
AU2015205268A1 (en) 2016-07-14
KR20180050770A (ko) 2018-05-15
EP3093021B1 (en) 2021-06-02
KR102111157B1 (ko) 2020-05-14
US20230372316A1 (en) 2023-11-23
JP7170020B2 (ja) 2022-11-11
KR101858373B1 (ko) 2018-05-15
JP2022189964A (ja) 2022-12-22
CN105828817A (zh) 2016-08-03
IL246654A0 (en) 2016-08-31
GEP20186916B (en) 2018-11-12
PH12016501327A1 (en) 2017-02-06
KR20210032547A (ko) 2021-03-24

Similar Documents

Publication Publication Date Title
MY166210A (en) Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
MX2021007432A (es) Compuestos y composiciones para inhibir la actividad de shp2.
TN2016000268A1 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2.
MY179951A (en) Pharmaceutical composition containing pyridylaminoacetic acid compound
MY189761A (en) Quinazoline derivatives used to treat hiv
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
AR102198A1 (es) Proceso para reducir partículas subvisibles en una formulación farmacéutica
WO2014039903A3 (en) Stable aqueous formulations of adalimumab
EA201690752A1 (ru) Ингибиторы g12c kras
SG10201909545XA (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
WO2016105525A3 (en) Novel pyrimidines as egfr inhibitors and methods of treating disorders
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
EA201692000A1 (ru) Макроциклические производные пиридина
MX2020007554A (es) Formulacion farmaceutica que comprende esomeprazol y bicarbonato de sodio.
HK1251566A1 (zh) 作为hdac1/2抑制剂的呱啶衍生物
HK1249504A1 (zh) 用作溴结构域抑制剂的吡啶酮二甲酰胺
EA201500821A1 (ru) Производные 2-замещенных-6-биарилметиламино-9-циклопентил-9н-пуринов, их использование в качестве лекарственных средств и фармацевтических составов
IN2013CH05441A (enExample)
EA201600122A1 (ru) Новые изоиндолиновые или изохинолиновые соединения, способ их получения и фармацевтические композиции, содержащие их
HK1257171A1 (zh) 間變性淋巴瘤激酶(alk)和絲氨酸富集蛋白激酶 (sppk)的抑制劑及其使用方法
EA201691741A1 (ru) Фармацевтическая композиция
EA201790699A1 (ru) Стабилизированные производные адреномедуллина и их применение
EP3372231A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PURPOSES OF CANCER IMMUNOTHERAPY AND / OR IMMUNOSTIMULATION WITH HETEROCYCLIC DIAMINO-CARBOXAMIDE COMPOUND AS AN ACTIVE SUBSTANCE